leisure time -WSS

leisure time

author：hotspot 2025-10-01 11:46:48 - browse：17

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Roche acquires Telavant from Roivant, adding experimental IBD treatment

hotspot

WSS

MD Anderson's Padmanee Sharma responds to research credit suit

Roche drug slashes death risk in early

Medicare Advantage enrollment hits roughly 33.4 million

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

New CMS data security rules will hurt Medicare, Medicaid research

In 'major milestone,' FDA approves first cell therapy for solid tumors

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Medicare details structure of new drug price negotiation program

Roivant's CEO is a star, but biotech's black hole persists

Apple is now the first public company to be valued at $3 trillion

New study raises questions about niacin and heart health

Medical leaders decry Supreme Court decision on affirmative action

A new drug could help frostbite victims avoid its ravages

Guidelines to prevent youth baseball injuries need more muscle

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

ChatGPT in medicine: STAT answers readers' burning questions

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

entertainment

J&J lung cancer data amount to new salvo against AstraZeneca

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Roivant's CEO is a star, but biotech's black hole persists

Flagship Pioneering startup Sonata Therapeutics lays off 21

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Wikipedia

hotspot

hotspot

entertainment